Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

HOECHST MARION ROUSSEL

Home Clinical Trial Sponsors and OrganizationsHOECHST MARION ROUSSEL

HOECHST MARION ROUSSEL

CLOSED

107 S Rosehill Rd, Lone Jack, Missouri, United StatesPrivate

Part of AVENTIS PHARMA

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

4

0 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 2

3

75.0%

Phase 1

1

25.0%

Trial Status Distribution

Completed

4

100.0%

Clinical Trials

Trials sponsored by this organization (4)

The Safety and Effectiveness of HBY 097 Used With or Without AZT in HIV-Infected Patients Who Have Mild or No Symptoms

144 participants

A Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients

200 participants

A Study of MDL 28,574A in HIV-Infected Patients

A Randomized, Double-Blind Active-Controlled, Dose-Ranging Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients

200 participants

Approvals

No approval data available

News

iQure Pharma Appoints Former UCB Chief Medical Officer Iris Loew-Friedrich as Clinical and R&D Advisor

- iQure Pharma, a clinical-stage biotech company developing treatments for CNS disorders through glutamate balance restoration, has appointed Prof. Dr. Iris Loew-Friedrich as Clinical and R&D Advisor. - Loew-Friedrich brings over 30 years of global pharmaceutical leadership experience, having served as Executive Vice President, Chief Medical Officer, and Head of Development at UCB from 2008 to 2024. - Her leadership at UCB contributed to the regulatory approvals of multiple drugs including bimekizumab, rozanolixizumab, zilucoplan, brivaracetam, and romosozumab across U.S., EU, and international markets. - The appointment strengthens iQure's clinical development capabilities as the company advances its lead asset iQ-007, a first-in-class oral small molecule currently in Phase 1 development for treatment-resistant epilepsy.

On this page

Overview
Clinical Trials4
Approvals
News1

Back to Organizations